SCM
THRD

Stonepine Capital Management’s Third Harmonic Bio THRD Stock Holding History

Stonepine Capital Management’s Portfolio THRD Stock Details THRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-212,783
Closed -$738K – 83
2025
Q1 		$738K Buy
+212,783
New +$1.03M 0.72% 29
2023
Q3 		– Sell
-2,793,149
Closed -$13.4M – 25
2023
Q2 		$13.4M Sell
2,793,149
-338,846
-11% -$1.61M 4.85% 8
2023
Q1 		$12.9M Buy
3,131,995
+1,116,694
+55% +$4.74M 4.33% 8
2022
Q4 		$8.67M Buy
+2,015,301
New +$33.7M 3.65% 8

Other funds holding THRD

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Stonepine Capital Management's THRD Position: Q2 2025 in Review

Stonepine Capital Management sold out of Third Harmonic Bio (THRD) in Q2 2025, closing a stake of 212,783 shares — an estimated $738K sold.

Stonepine Capital Management first reported a position in THRD in Q4 2022 and held it in 4 quarters. The position peaked at $13.4M in Q2 2023. 105 funds tracked by Wall St. Rank hold THRD as of Q2 2025.

  • Stonepine Capital Management reported no remaining Third Harmonic Bio position as of Q2 2025 after selling out during the quarter.
  • Stonepine Capital Management sold 212,783 Third Harmonic Bio shares in Q2 2025, an estimated $738K.
  • Stonepine Capital Management first reported a position in Third Harmonic Bio in Q4 2022 and held it in 4 quarters.
  • Stonepine Capital Management's Third Harmonic Bio position peaked at $13.4M in Q2 2023.
  • 105 funds tracked by Wall St. Rank held Third Harmonic Bio as of Q2 2025.

Based on Stonepine Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.